LumiraDx Investor Presentation Deck

We Have Launched a Broad Menu of Tests with Lab Comparable Performance TAM¹ Market² TAM¹ Market² SARS-CoV-2 Ag INR Test US / EU / JP / BR $500M T EU SARS-CoV-2 Ab Tost Coagulation SARS-CoV-2 Ag PoolTest $12B D-Dimer Tost $700M EU SARS-CoV-2 Ag Utha Test EU CRP Test BOCA Inflammation $300M EU GALLINE SARS-CoV-2 Ag Uttra Pool Test Respiratory & FAR SARS-CON-2 The A/B Ted $1.5-3B EU / JP Diabetes HbAlc Test $1.3B EU Lattia KASV SARS-CoV-2 & RSV Tos! $200-400M EU Cardiovascular Maste NT-proBNP Test $350M EU amira COVID-19 lumiraDx™ (2) Markets with regulatory authorization. Products available in the market or planned to launch in 2022. Copyright ©2022 LuminaDx Ltd. All Rights Reserved. Worldwide $9B EU Enzyme RNA STAR COVID RNA STAR COVID RNA STAR Complete Molecular ■♥ COVID & Flu RNA STAR Complete $12B/$12B/$1B Area Legend Qualitative Immunoassay US / EU Quantitative Immunoassay (1) 2021 Global Total Addressable Market ("TAM"), based on our assumptions, including the (a) existing market sizes, (b) centrallab market that could move to the POC, and (c) expansion of diagnostic testing. COVID TAMs difficult to estimate at present, may overlap with each other. 12

View entire presentation